TRAIN-HEART Network

The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


People

TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.


Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


Contact

If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.





News

Role of the epigenome in heart failure

The group of Prof. Condorelli (Humanitas Hospital Milan, Italy) recently published a review on the impact of environmental factors, such as diet, smoking, and lifestyle, as pathogenic factors in heart failure development. Epigenetic changes can arise as a consequence of these factors.

More

The Porto meeting of the TRAIN-HEART network was a major success

From 16-18 February the first hybrid TRAIN-HEART network meeting was organised by our partner: University of Porto.



More

A spray to protect against lung damage from Covid-19 developed by the TRAIN-HEART group at TUM (Munich)

The research team led by Stefan Engelhardt, Professor of Pharmacology and Toxicology at the Technical University of Munich (TUM) and Principal Investigator in the TRAIN-HEART network, has developed a new RNA drug that can prevent inflammatory lung damage. The German Federal Ministry of Education and Research (BMBF) is supporting further development of the drug as part of the TUM spin-off "rnatics" with around 7 million euros.

More

Checkout the new and impressive paper "Nano-miR-133a Replacement Therapy Blunts Pressure Overload–Induced Heart Failure"

Great work conducted by the groups at Humanitas Mirasole (Milan, Italy) and led by Dr. Daniele Catalucci.

More

The long non-coding RNA NRON promotes the development of cardiac hypertrophyin the murine heart

Two TRAIN-HEART groups teamed up (Hannover Medical School & Technical University Munich) to elucdiate the promoting role of long non-coding RNA NRON in the development of cardiac hypertrophy in the murine heart.

More